Sort
15,440 grants matching “organoids”
Novel therapy for Fragile X syndrome
$998,958Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2021 · MH
Micro-Organospheres Drug Screen to Lead Care (MODEL): a Precision Oncology Platform to Guide Breast Cancer Therapy
$998,506Daniel Delubac · Xilis, Inc. · R44 · FY2023 · CA
A 3D vascularized islet biomimetic to model type 1 diabetes
$998,312Maike Sander · University Of California, San Diego · UH3 · FY2023 · DK
Precision microRNA medicine in cancer
$997,500Frank J. Slack · Beth Israel Deaconess Medical Center · R35 · FY2024 · CA
Adaptable tissue-specific endothelial cells for organ regeneration
$997,417Shahin Rafii · Weill Medical Coll Of Cornell Univ · R35 · FY2024 · HL
STING-dependent Intestinal Regeneration upon Radiation Injury
$997,217Jian Yu · University Of Southern California · R01 · FY2025 · CA
Tracking the evolution of breast cancer through single cell analyses of premalignant breast tissues from women at high risk for cancer development
$996,660Joan Siefert Brugge · Harvard Medical School · R35 · FY2022 · CA
Targeting Epigenetic Circuits in B-Cell Lymphomas
$996,660Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R35 · FY2022 · CA
Tracking the evolution of breast cancer through single cell analyses of premalignant breast tissues from women at high risk for cancer development
$996,660Joan Siefert Brugge · Harvard Medical School · R35 · FY2023 · CA
Neuronal and Progenitor/Stem Cell Function During Salivary Gland Development
$996,494Matthew Hoffman · National Institute Of Dental & Craniofacial Research · ZIA · FY2019 · DE
PDX Trial Center for Breast Cancer Therapy
$996,258Alana L Welm · University Of Utah · U54 · FY2024 · CA
Prion protein function in redox homeostasis and associated failure in prion disease
$995,382Cathryn Haigh · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
1/2 Cross modal integration of molecular and physiological networks in ASD
$993,129Daniel H Geschwind · University Of California Los Angeles · U01 · FY2021 · MH
Developing novel LOX inhibitors to target chemotherapy resistant TNBC
$992,932Ozgur Sahin · Loxigen, Inc. · R42 · FY2024 · CA
Minerals in Nutrition and Development
$991,390Rajini Rao · Johns Hopkins University · UC2 · FY2025 · HD
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia
$991,226Victor Nizet · University Of California, San Diego · R01 · FY2025 · AI
Impact of Matrix Viscoelasticity on Induced Pluripotent Stem Cell Morphogenesis
$990,839Ovijit Chaudhuri · Stanford University · · FY2022 · BIO
SBIR Phase II: Bacteriophage-Based Microbial Gene Therapy Platform for In Situ Engineering of Microbiomes
$989,854Michael Koeris · Vulcan Biologics, Inc. · · FY2021 · TIP
Development of synthetic sphingolipids for prostate cancer therapy
$989,405Alison Nicole McCracken · Siege Pharmaceuticals, Inc. · R44 · FY2021 · CA
The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis
$989,186Chetan Seshadri · University Of Washington · R01 · FY2025 · AI
Macrophage Polarization in Response to Infections and Inflammation
$988,702Pradipta Ghosh · University Of California, San Diego · R01 · FY2021 · AI
A 2D Intestinal Crypt Platform for Compound Screens
$988,431Bill Thelin · Altis Biosystems, Inc. · R44 · FY2022 · DK
Polymerase epsilon-based mouse and derived organoid models of intestinal cancer
$987,867Diego H Castrillon · Ut Southwestern Medical Center · R01 · FY2025 · CA
The role of stem cells and the microenvironment in gastrointestinal cancers
$987,000Timothy Cragin Wang · Columbia University Health Sciences · R35 · FY2023 · CA
Targeting Epigenetic Circuits in B-Cell Lymphomas
$986,490Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R35 · FY2019 · CA